```
FILE 'REGISTRY' ENTERED AT 14:20:28 ON 03 FEB 2004
                 E PALMITATE/CN
               1 S E3
L1
                  E PALMITIC ACID/CN
L6
               1 S E3
L7
               2 S L1 OR L6
     FILE 'HCAPLUS' ENTERED AT 14:30:29 ON 03 FEB 2004
               1 SEA FILE=REGISTRY ABB=ON PLU=ON PALMITATE/CN
1.1
               1 SEA FILE=REGISTRY ABB=ON PLU=ON "PALMITIC ACID"/CN
L6
               2 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L6
L7
           66608 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 OR PALMITATE OR
L9
                  HEXADECANOATE OR PALMITIC OR HEXADECANOIC OR HEXA(W) (DECA
                  NOATE OR DECANOIC)
               1 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND (FAT PAD(S)(?FOOT
L10
                   OR FEET))
L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:
                            2002:391493 HCAPLUS
DOCUMENT NUMBER:
                            136:391071
                            A method for restoring a fat-pad using a mixture
TITLE:
                            of fatty acids
                            Desrosiers, Eric Andre
INVENTOR(S):
PATENT ASSIGNEE(S):
                            Bio Syntech Canada Inc., Can.
                            PCT Int. Appl., 38 pp.
SOURCE:
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
                            English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
                           1
PATENT INFORMATION:
                        KIND
                               DATE
                                                APPLICATION NO.
     PATENT NO.
                               _____
                                                ______
                                                                   ----
                         A2
                               20020523
                                             WO 2001-CA1586
                                                                   20011114
     WO 2002039977
                        А3
     WO 2002039977
                               20021031
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
              NO, NZ, OM, PH, PL, PT, RO
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
              TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
              TD, TG
                                                                   20011029
     US 2002094959
                                                US 2001-55493
                               20020718
                         Α1
                               20020527
                                               AU 2002-18081
                                                                   20011114
     AU 2002018081
                         Α5
                                              EP 2001-996361
                               20030903
                                                                   20011114
     EP 1339393
                         A2
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
```

AB The present invention relates to a method for treating damaged or degenerated **fat pads** in a **foot** of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatible solution having

PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

Searcher: Shears 571-272-2528

US 2000-248228P

US 2001-55493

US 2000-248570P P 20001116

20001115

A 20011029

physicochem. and mech. properties substantially similar to a fatty acid mixture normally present in a healthy fat pad. For example, fatty acids, myristate 1.9%, palmitate 15.9%, stearate 1.7%, palmitoleate 12.3%, vaccenate 4.8%, oleate 46.4% and linoleate 17.0% (weight/weight) were combined in an amber glass bottle, warmed to 65°, and mixed using a magnetic stir plate. The mixture was sterilized by filtration and dispensed in aseptic conditions, by 5 mL aliquots, in amber glass vials, to avoid photooxidn. Each vial, stored at or below room temperature, can be used by first warming it up slightly above the m.p. of the mixture  $(37-40^{\circ})$ . The liquified solution is then drawn from the vial with a syringe fitted with a fine needle (26G). The plantar surface of the patient's foot is washed with soap, rinsed with water, dried, and prepared with 70% iso-Pr alc. and a sterile gauze wipe. The site of injection can first be anesthetized, and then injected within the atrophic fat pad, at about 1 cm below the surface of the skin. For the heel site, this injection site is directly above the calcaneus, where heel spur normally develops. The clinician can feel the increased resistance in the syringe as the fat pad becomes refilled.

IT 57-10-3, Palmitic acid, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (injection of biocompatible fatty acids mixture for restoring
 fat-pad in foot)

(FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 14:53:21 ON 03 FEB 2004)

1 S L10

L11 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

ACCESSION NUMBER:

2002-519362 [55] WPIDS

DOC. NO. CPI:

C2002-146945

TITLE:

L11

Treatment of damaged or degenerated fat pads comprises injection of biocompatible solution

comprises injection of biocompatible solution similar to fatty acid mixture normally present in

the healthy fat pad.

DERWENT CLASS:

A96 B05

INVENTOR(S):

DESROSIERS, E A

PATENT ASSIGNEE(S):

(DESR-I) DESROSIERS E A; (BIOS-N) BIO SYNTECH

CANADA INC

COUNTRY COUNT:

99

PATENT INFORMATION:

PATENT NO KIND DATE WEEK LA PG

WO 2002039977 A2 20020523 (200255)\* EN 38

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC

MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ

DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA

UG US UZ VN YU ZA ZW

US 2002094959 A1 20020718 (200255)

AU 2002018081 A 20020527 (200261)

EP 1339393 A2 20030903 (200365) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

Searcher : Shears 571-272-2528

## APPLICATION DETAILS:

PATENT NO KIND		APPLICATION	DATE
WO 2002039977 A2		WO 2001-CA1586	20011114
US 2002094959 A1		US 2000-248228P	20001115
	Provisional	US 2000-248570P	20001116
		US 2001-55493	20011029
AU 2002018081 A		AU 2002-18081	20011114
EP 1339393 A2		EP 2001-996361	20011114
		WO 2001-CA1586	20011114

#### FILING DETAILS:

PA	TENT NO	KIND				ENT NO
AU	200201808					2002039977
EP	1339393	Δ2	Rasad	on	TATO	2002039977

PRIORITY APPLN. INFO: US 2001-55493 20011029; US 2000-248228P 20001115; US 2000-248570P 20001116

AN 2002-519362 [55] WPIDS

AB WO 200239977 A UPAB: 20020829

NOVELTY - Treatment of damaged or degenerated fat pads involves injecting into the pad a biocompatible solution with an intrinsic viscosity above 5 mPa.s at physiological temperature, substantially similar to a fatty acid mixture which is normally present in the healthy fat pad.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the use of the biocompatible solution in the manufacture of a medicament for treatment of damaged or degenerated fat pads.

ACTIVITY - Analgesic.

MECHANISM OF ACTION - None given.

USE - In the treatment of damaged or degenerated **fat pad** of a host located in the sub-calcaneal, outside arch or metatarsal of a **foot** (claimed).

ADVANTAGE - The thickness of the damaged or degenerated fat-pad is restored and consequently their cushioning function. Also the solution is injectable, non-toxic, biocompatible and have a sufficiently long residence time in the pad providing a safe and long lasting effect.

Dwg.0/3

FILE 'HCAPLUS' ENTERED AT 14:54:14 ON 03 FEB 2004

L12 113 S L9 AND (?FOOT OR FEET)

L13 1 S L12 AND FAT PAD

L14 0 S L13 NOT L10

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO' ENTERED AT 14:55:20 ON 03 FEB 2004

L15 2 S L13

L16 1 S L15 NOT L11

L16 ANSWER 1 OF 1 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 93281488 EMBASE

DOCUMENT NUMBER: 1993281488

TITLE: Fatty acid composition of normal and atrophied heel

Searcher: Shears 571-272-2528

fat pad.

AUTHOR: Buschmann W.R.; Hudgins L.C.; Kummer F.; Desai P.;

Jahss M.H.

CORPORATE SOURCE: Department of Orthopaedic Surgery, Bronx Lebanon

Hospital Center, 1650 Selwyn Ave., Bronx, NY 10457,

United States

SOURCE: Foot and Ankle, (1993) 14/7 (389-394).

ISSN: 0198-0211 CODEN: FANKDJ

COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article

FILE SEGMENT:

029 Clinical Biochemistry

033

Orthopedic Surgery

LANGUAGE:

English

SUMMARY LANGUAGE: English

Capillary gas-liquid chromatography was used to analyze the fatty acid composition of normal heel fat pads from subjects without systemic disease (N = 8) and atrophied heels from

patients with diabetic peripheral neuropathy (N = 4), rheumatoid arthritis (N = 1), peripheral vascular disease (N = 1), and hereditary sensory neuropathy (N = 1). In the normal subjects, the fatty acid composition of subcutaneous abdominal fat'was also obtained for comparison. Three saturated fatty acids (myristate,

palmitate, and stearate) and four unsaturated fatty acids (palmitoleate, oleate, vaccenate, and linoleate) comprised over 90% of the total fatty acid composition. Higher percentages of unsaturated fatty acids and lower percentages of saturated fatty acids were found in the normal heel fat pads

when compared to subcutaneous abdominal fat. The increase in the ratio of unsaturated fatty acids to saturated fatty acids (4.4 versus 2.5, P < .01) may decrease triglyceride viscosity and enhance the biomechanical efficiency of the heel fat pad

. Though the number of patients is small, no statistically significant compositional differences were noted between the heel fat from normal subjects and from subjects with peripheral neuropathies, rheumatoid arthritis, or peripheral vascular disease. However, the heel fatty acid composition of the one subject with a hereditary sensory neuropathy was less unsaturated and more saturated than normal with a ratio of unsaturates to saturates similar to that of the abdomen (2.8).

FILE 'HCAPLUS' ENTERED AT 14:55:56 ON 03 FEB 2004

L17 2 S FAT PAD(S) (?FOOT OR FEET)

L18 1 S L17 NOT L10

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1972:95232 HCAPLUS

DOCUMENT NUMBER: 76:95232

TITLE: Induction of edema in the adrenalectomized rat

by D-galactosamine. Mechanism of action of

galactosamine

AUTHOR(S): Reutter, W.; Hassels, B.; Lesch, R.

CORPORATE SOURCE: Biochem. Inst., Univ. Freiburg, Freiburg/Br.,

Fed. Rep. Ger.

SOURCE: Naturwissenschaften (1971), 58(11), 576

CODEN: NATWAY; ISSN: 0028-1042

DOCUMENT TYPE: Journal

LANGUAGE: English

Adrenalectomized rats given a single dose of D-galactosamine (I)

Searcher : Shears 571-272-2528

```
[7535-00-4] (375 mg I-HCl/kg, i.p.) developed excessive edema in the
     s.c. tissue, especially in the ears, feet, and nose, abdominal
     cavity edema in the mesenterial fat pads, and
     enhanced ascites production. The induction of edema was accompanied
     by a fall in plasma protein to .sim.60% of normal values.
     Glucocorticoids prevented the formation of edema.
ΙT
     Proteins
     RL: BIOL (Biological study)
         (blood-plasma, in galactosamine-induced edema)
ΙT
     Adrenalectomy
         (edema from galactosamine in)
IΤ
     Edema
         (from galactosamine, after adrenalectomy)
     7535-00-4
     RL: PRP (Properties)
        (edema from, in adrenalectomy)
     FILE 'HCAPLUS' ENTERED AT 14:55:56 ON 03 FEB 2004
L17
              2-S-FAT PAD(S) (?FOOT OR FEET)
L18-
              1-S-L17-NOT-L10
     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 14:56:39 ON 03 FEB 2004
L17
              2 SEA FILE=HCAPLUS ABB=ON PLU=ON FAT PAD(S)(?FOOT OR
L19
             91 SEA L17
L20
              5 SEA L19(S) (DAMAG? OR DEGENERAT? OR DE GENERAT? OR
                RESTOR?)
L21
             4 L20 NOT (L11 OR L16)
=> dup rem 121
PROCESSING COMPLETED FOR L21
              4 DUP REM L21 (0 DUPLICATES REMOVED)
    ANSWER 1 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
ACCESSION NUMBER:
                    2001258964 EMBASE
TITLE:
                    Metatarsal head preservation in forefoot arthroplasty
                    and the correction of severe claw toe deformity.
AUTHOR:
                    Briggs P.J.; Stainsby G.D.
CORPORATE SOURCE:
                    Dr. P.J. Briggs, Consultant Orthopoedic Surgeon, 34
                    Chollerford Close, Newcastle upon Tyne NE3 4RN,
                    United Kingdom. peterjbriggs@btinternet.com
SOURCE:
                    Foot and Ankle Surgery, (2001) 7/2 (93-101).
                    Refs: 42
                    ISSN: 1268-7731 CODEN: FASUF8
COUNTRY:
                    United Kingdom
DOCUMENT TYPE:
                    Journal; Article
FILE SEGMENT:
                    033
                            Orthopedic Surgery
LANGUAGE:
                    English
SUMMARY LANGUAGE:
                    English
    A surgical technique is described that replaces and maintains the
    position of the metatarsophalangeal joint plantar plate and
     forefoot fat pad underneath the
    metatarsal heads in the correction of severe claw toes and in
    forefoot arthroplasty. Sixty-nine feet in 52
```

Searcher: Shears 571-272-2528

patients after single lesser toe correction and 41 feet in 29 patients after multiple toe correction were reviewed between 1 and 11 years following surgery. Most patients undergoing multiple toe correction suffered rheumatoid arthritis. Following single toe surgery, patient satisfaction was good or excellent in 83% with complete relief of pain in 80% of patients. Recurrent toe deformity was associated with the development of deformity in an adjacent toe. Following multiple toe surgery, patient satisfaction was good or excellent in 93% with complete relief of pain in 93%. The need for chiropody skin care, insoles and surgical shoes was reduced. Metatarsalgia associated with claw toe deformity is relieved by reducing the downward force on the metatarsal head and by restoring the weight-bearing function of the forefoot fat pad. Its position is governed by the length of the plantar aponeurosis and so the importance of preserving the metatarsal heads and metatarsal length is emphasized.

L22 ANSWER 2 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1999407269 EMBASE

TITLE: Subtalar arthrodesis with correction of deformity

after fractures of the os calcis.

AUTHOR: Marti R.K.; De Heus J.A.C.; Roolker W.; Poolman R.W.;

Besselaar P.P.

CORPORATE SOURCE: Dr. W. Roolker, Department of Orthopaedics-G4,

University of Amsterdam, Meibergdreef 9, 1105 AZ

Amsterdam, Netherlands

SOURCE: Journal of Bone and Joint Surgery - Series B, (1999)

81/4 (611-616).

Refs: 27

ISSN: 0301-620X CODEN: JBSUAK

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 014 Radiology

033 Orthopedic Surgery

LANGUAGE: English SUMMARY LANGUAGE: English

We have reviewed the long-term results of 22 patients (23 fusions) with fractures of the os calcis, who had subtalar arthrodesis with correction of the deformity between 1975 and 1991. The mean follow-up was nine years (5 to 20). All patients were evaluated according to a modified foot score. A radiological assessment was used in which linear and angular variables were measured including the fibulocalcaneal abutment, the height of the heel and fat pad, the angle of the arch and the lateral talocalcaneal and the lateral talar declination angles. The technique used restores the normal relationship between the hindfoot and midfoot and corrects the height of the heel. This leads to better biomechanical balance of the neighbouring joints and gives a favourable clinical outcome. The modified foot score showed a good or excellent result in 51% of the feet. Residual complaints were mostly due to problems with the soft tissues. Subjectively, an excellent or good score was achieved in 78% of the cases. After statistical analysis, except for the height of the heel and the degenerative changes in the calcaneocuboid joint, no significant difference was found in the measured variables between the operated and the

Searcher: Shears 571-272-2528

contralateral side.

L22 ANSWER 3 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS

RESERVED, on STN

ACCESSION NUMBER: 90275204 EMBASE

DOCUMENT NUMBER:

1990275204

TITLE:

Neuromas of the heel.

AUTHOR:

Davidson M.R.; Copoloff J.A.

CORPORATE SOURCE:

California College of Podiatric Medicine, San

Francisco, CA, United States

SOURCE:

Clinics in Podiatric Medicine and Surgery, (1990) 7/2

(271-288).

ISSN: 0891-8422 CODEN: CPSUEB

COUNTRY:

United States

DOCUMENT TYPE:

Journal; General Review

FILE SEGMENT: 800

Neurology and Neurosurgery

033 Orthopedic Surgery

LANGUAGE:

English English

SUMMARY LANGUAGE:

Homo sapiens evolved barefoot on grassy plains, forest

floors, and sandy beaches. Prehistoric man sat on his haunches all day and for a few hours would hunt for food. Later he would return to his campsite and squat for the rest of the day by the fire performing tribal rituals, repairing and fabricating weapons, and celebrating the day's catch. Today, civilized people spend most of their waking hours working in unnatural environments of unyielding surfaces with unnatural footgear. With the evolution of civilization came the evolution of heel pain. Health care providers, for the most part, have been unsuccessful in treating chronic heel pain. In this article, we hope to dispel some of the myths surrounding heel pain and spark a new understanding of the cause of this painful foot problem which has plagued man since the dawn of civilized society. Heel pain accounts for a majority of all adult foot complaints among the world's population. A number of different entities may cause heel pain. The less common etiologies may be gonococcal, diabetes, gout, and the various types of arthritities. The most common cause of heel pain seen in the world today in adults, however, may be attributed to the chronic microtrauma of heel strike in walking or running. This repeated microtrauma ultimately leads to damage of the calcaneal fat pad and injury to the neural and vascular

components in the heel.

L22 ANSWER 4 OF 4 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 83158703 EMBASE

DOCUMENT NUMBER:

1983158703

TITLE:

AUTHOR:

Metatarsal head resection in the treatment of the

rheumatoid forefoot.

CORPORATE SOURCE:

Goldie I.; Bremell T.; Althoff B.; Irstam L.

Dep. Orthop. Surg., Karolinska Sjukhuset, S 10064

Stockholm, Sweden

SOURCE:

Scandinavian Journal of Rheumatology, (1983) 12/2

(106-112).

CODEN: SJRHAT

COUNTRY:

Sweden

DOCUMENT TYPE:

Journal

FILE SEGMENT:

031 Arthritis and Rheumatism

Searcher : Shears 571-272-2528

033 Orthopedic Surgery

Leprosy and other Mycobacterial Diseases 051

LANGUAGE:

AB

English When conservative treatment in the management of the painful rheumatoid forefoot fails, surgery should be advocated. The aim is to relieve the sole from pressure on the metatarsal heads, which causes callosities on and pain in the forefoot . Various surgical procedures have been described, but they have in common to replace or remove the fat pad under the metatarsal phalangeal joints, to resect the metatarsal heads and, in doing this, restore the metatarsal ends to a flat arc. For if the intermediate metatarsals are left too long, new

pressure points may develop, with ensuing pain. In this investigation a 41/2-year follow-up is presented of 32 patients operated on with metatarsal head resection in 59 feet. Twenty-two patients representing 39 feet were very satisfied, whereas 8 patients representing 15 feet were dissatisfied. Walking ability improved considerably; standing on toes improved; muscle power of toes improved. Despite attempting to maintain the metatarsal arc as a flat curve, this proved to be uneven in 25 feet, but did not jeopardize the results. The complications were minor and did not influence the final results. These, however, were decidedly influenced by the functional class of the patient at the time of investigation. Surgical management of the painful rheumatoid forefoot appears to be a recommendable procedure.

FILE 'HOME' ENTERED AT 14:58:22 ON 03 FEB 2004

571-272-2528 Searcher Shears